Introduction
Pancreatic cancer is one of the leading causes of tumorrelated mortalities. The prognosis of patients after complete resection is poor, and more than 50% of patients develop tumor recurrence at distant or locoregional sites, with an estimated 5-year survival of only 20% (Kayahara et al., 1993; Nitecki et al., 1995; Staley et al., 1996; Sener et al., 1999; Li et al., 2004) . The addition of chemotherapy and/or radiotherapy to surgical resection is important (Rothenberg et al., 1996; Oettle et al., 2007; Evans et al., 2008) , however, the clinical response rate remains still unsatisfactory (Burris et al., 1997) .
Clinicopathologic parameters, such as positive lymph nodes, positive margins and histological type, were well-known as prognostic factors for surgical outcome (Geer and Brennan, 1993; Sohn et al., 2000) . Recently, numerous genetic and epigenetic alterations were revealed to occur during the development of pancreatic adenocarcinoma and some molecules were reported to be useful for the prediction of prognosis (Infante et al., 2007; Kahlert et al., 2009; Manuyakorn et al., 2010) . These factors leads to the selection of patients who actually need to receive the intensive post-operative therapy based on significant parameters. However, there are few valuable biomarkers useful for clinical application.
The epithelial cell adhesion molecule (Ep-CAM) is a 40 kDa glycosylated transmembrane cell surface epithelial protein encoded by the TACSTD1 gene (Calabrese et al., 2001) . Previous studies have documented Ep-CAM expression is in a wide spectrum of normal adult epithelial tissues (Momburg et al., 1987; Litvinov et al., 1996; Cirulli et al., 1998) and abundant Ep-CAM expression is also seen across most epithelial malignancies including pancreatic cancer (Edwards et al., 1986; Ross et al., 1986; Zhang et al., 1998; Balzar et al., 1999b) . Furthermore, several investigators reported that Ep-CAM was related to the maintenance of stem cells (Li et al., 2007; Yamashita et al., 2008; Gonzalez et al., 2009) . For these reasons, this molecule has attracted attention as a tumor marker and as target for cancer therapy (Armstrong and Eck, 2003; Winter et al., 2003) . Despite overexpression of Ep-CAM on cancer cells, its role in tumor progression is still controversial. Tai et al. (2007) reported that silencing of Ep-CAM was related to tumor invasion and progression, and Jojovic et al. (1998) showed that Ep-CAM expression could be transiently lost during the process of metastasis.
The influence of Ep-CAM expression to clinical prognosis is also a matter of debate. There are some clinical reports about the relation of Ep-CAM expression to the prognosis, but the significance is uncertain; high-Ep-CAM expression was described as a good prognostic factor (Seligson et al., 2004; Songun et al., 2005; Kimura et al., 2007) , while in some reports highEp-CAM expression led to poor prognosis (Gastl et al., 2000; Varga et al., 2004; Stoecklein et al., 2006) . Following this discrepancy, Ep-CAM may have a different role in each type of cancer. To the present, it is not clear about the impact of Ep-CAM expression on the cancer cell activity or the prognosis after resection in pancreatic cancer.
In this study, we examined the relationship between Ep-CAM expression and malignant potential to elucidate the clinical significance of Ep-CAM expression in pancreatic cancer.
Results
The transfection of Ep-CAM and cell activity Ep-CAM was transfected successfully to three pancreatic cancer cell lines (MiaPaCa-2, Panc1 and PSN1) and the Ep-CAM expression was confirmed by RT-PCR ( Figure 1a ). All of Ep-CAM-transfected cell lines showed no morphological difference from parental cells (data are not shown). For proliferation assay, Ep-CAM-transfected cells of PSN1 showed significantly lower growth curve than the mock-transfected cells or the parental cells (Figure 1b) , while Ep-CAM-transfected cells of the other two cell lines showed the same growth curve as that of mock transfected or parental cells (Supplementary Figure 1) . For invasion assay and migration assay, in all the three cell lines, Ep-CAM-transfected cells showed the less ability of invasion and migration than the mock transfected or parental cells (Figure 1c ). Especially in PSN1, which showed the significant difference of growth curve between the Ep-CAMtransfected cells and the others, the ability of invasion and migration in Ep-CAM-transfected cells dramatically decreased (Figure 1d, Supplementary Figure 2) .
The immunostaining of Ep-CAM
We examined the Ep-CAM expression in 95 neutralbuffered formalin-fixed and paraffin-embedded blocks obtained from pancreatic cancer patients receiving the radical surgery at two different institutes, Osaka University Hospitals (Osaka Univ.) and Osaka Medical Center for Cancer and Cardiovascular Diseases (OMCC). Ep-CAM expression was seen mainly in plasma membrane of cancer cells and immunostaining showed a fine granular pattern (Figure 2a) . Figure 2b showed the scoring of Ep-CAM expression in 95 pancreatic cancer specimens and these patients were divided into two groups, 'high-expression group' with more than four of scoring and 'low-expression group' with four and less according to the previous report (Gastl et al., 2000) . This score was the average of scoring from triplicate cancer tissues in each patient. Among 95 specimens, only 6 specimens showed no Ep-CAM expression and this may be because pancreatic cancer generally derives from pancreatic epithelial cells. There were 47 patients in high-expression group, whereas 48 patients in low-expression group. There were no significant differences between patients with high and low-tumoral Ep-CAM expression with respect to age, sex, histopathological type (poor/mod/well), pathological depth of tumor (pT1/T2/T3), pathological lymph node metastasis (pN0/N1/M1lym), pathological stage (pStage IA/IB/IIA/IIB/IV) and the presence or absence of recurrent (Table 1) . When examining the difference separately in each institute, in the same way there were no significant clinicopathological differences between two groups (Supplementary Table 1 ).
The clinical significance of Ep-CAM expression
The median overall survival of all patients was 17.6 months (4.3-145) and 5-year survival rate was 24.1%, while the median disease-free survival was 12.2 months (2-145). The Kaplan-Meier overall survival estimates were significantly better for patients with high-Ep-CAM expression compared with those with low-Ep-CAM expression levels (3-year survival; 56.2 versus 19.2%, P ¼ 0.0018) (Figure 3a) . When examining the overall survival separately in each institute, the Ep-CAM highexpression group showed better prognosis than lowexpression group both in Osaka Univ. (3-year survival; 55.4 versus 19.7%, P ¼ 0.016) and OMCC (3-year survival; 58.7 versus 17.8%, P ¼ 0.048) (Supplementary Figure 3) .
With regard to disease-free survival, high-Ep-CAM expression levels were significantly associated with better outcome in all 95 patients (3-year survival; 40.3 versus 14.4%, P ¼ 0.038). However, there was no significant difference in disease-free survival when examining separately in each institute (data are not shown).
In addition, concerning the influence of Ep-CAM in the pancreatic cancer analyzed in divided two groups, LN-negative group and positive group, LN-negative group showed bigger difference of prognosis between Ep-CAM high and low than LN-positive group in this study (Supplementary Figure 4) . This may be partially because cancer cell in Ep-CAM low expression group possesses high potential of invasion and migration.
The existence of lymph node metastasis is generally recognized as a strong prognostic factor in pancreatic cancer patients (Geer and Brennan, 1993 ; Sohn et al., , and LN-negative patients significantly showed good prognosis in univariate and multivariate analysis in this study (Table 2) . Meanwhile, Ep-CAM expression showed no relationship with LN status and also showed an independent prognostic factor in multivariate analysis. In the patients with no lymph node metastasis who receive less prognostic influence from lymph node status, Ep-CAM can make a strong impact on the prognosis.
Univariate and multivariate analysis of factors associated with prognosis We investigated the prognostic significance of various clinicopathological factors in pancreatic cancer patients who underwent radical resection. For overall survival, univariate analysis showed that the pathological type and absence or presence of lymph node metastases were prognostically significant as well as Ep-CAM expression, and Ep-CAM expression was identified as the most independent prognostic factor in multivariate analysis though the other two factors were also independent prognostic factor ( Table 2 ). For disease-free survival, univariate analysis showed that these three factors were prognostically significant, but Ep-CAM was not identified as independent prognostic factor in multivariate analysis (Supplementary Table 2 ).
The role of Ep-CAM in pancreatic cancer
To elucidate the mechanism of Ep-CAM to suppress the migration and invasion potential in pancreatic cancer, we examined the epithelial mesenchymal transition (EMT)-related gene expression of Ep-CAM-transfected cell lines and protein expression of resected pancreatic cancer tissues in 68 patients who received surgery at Osaka Univ. At first, EMT-related genes, E-cadherin, cytokeratin 19 (CK19), Vimentin, fibronectin and asmooth muscle antibody (a-SMA) were examined in Ep-CAM-transfected cell lines. E-cadherin was significantly high expressed in Ep-CAM-transfected cell lines compared with parental and mock-transfected cell lines, but other genes showed no significant difference among them although only vimentin showed the tendency to decrease in Ep-CAM-transfected cell lines (Figure 4 , Supplementary Figure 5 ). In pancreatic cancer tissues, we performed immunohistochemistry to evaluate EMTrelated protein expression with dividing 68 patients into four groups according to the expression level; negative, weak, moderate and strong, and examined the difference of Ep-CAM scoring among these four groups. Ecadherin protein expression was significantly related to Ep-CAM expression; Ep-CAM score in each group increased according to the elevation of E-cadherin protein expression, although other related molecules did not show any difference among four groups (Figure 4, Supplementary Figure 6 ).
Discussion
Ep-CAM can be thought of as having a dual role in tumor malignancy (Balzar et al., 1999a) . It has a role as an adhesion molecule that suppresses metastasis by holding cells in place (Basak et al., 1998) , while induces dissociation of cadherin-mediated adhesion to promote invasion and metastasis (Gumbiner, 1996; Litvinov et al., 1997) . For example, Gosens et al. (2007) reported that Ep-CAM expression decreased in budding part of colorectal cancer and Rao et al. (2005) reported that Ep-CAM expression was lower in circulating tumors cells compared with their corresponding primary tumors. The significance of Ep-CAM expression in pancreatic cancer H Akita et al
Meanwhile, there are appreciable argue and discussion about the molecular biological role of Ep-CAM for oncology, such as cell proliferation and invasion. Munz et al. (2004) reported that Ep-CAM upregulated c-myc and induced cell proliferation, and Osta et al. (2004) reported that specific ablation of Ep-CAM expression using RNA interference resulted in a dramatic decrease in the invasive potential of breast cancer cell lines. Furthermore, Sankpal et al. (2009) reported that transcriptional repression of Ep-CAM expression activated breast cancer invasion controlled by p53 protein. Although these results were outstanding and should not be deprecated, most of these results were applied for some cancer types, such as breast cancer and hepatocellular carcinoma, so the discrepancy may be explained by differences in tissue of origin and mechanisms of carcinogenesis among original cancer cells. In pancreatic cancer, our result indicates that Ep-CAM suppresses the potential of both invasion and migration leading to good prognosis after radical resection following discussion.
The clinical significance of Ep-CAM expression is also hard to assess. Some reported it was a good prognostic factor in renal cell carcinoma (Seligson et al., 2004) , gastric cancer (Songun et al., 2005) and esophageal cancer (Kimura et al., 2007) ; while a poor prognostic factor in breast cancer (Gastl et al., 2000; Schmidt et al., 2008) , gallbladder cancer (Varga et al., 2004) and esophageal cancer (Stoecklein et al., 2006) . The significance of Ep-CAM expression in pancreatic cancer H Akita et al
To our knowledge, there was only one report regarding the relationship between Ep-CAM expression and the prognosis of pancreatic cancer patients (Fong et al., 2008) . According to their opinion, no significant difference was shown in the prognosis between the highand low-Ep-CAM expression in all 153 patients, but in the subgroups of patients with advanced disease, highEp-CAM expression group showed significantly poor prognosis compared with low expression. However, among 153 patients enrolled in this study, 91 (60%, more than half) patients did not receive radical surgery; 62 (40%) patients received palliative surgery and 29 (20%) patients were inoperable. In such a condition, the relationship between Ep-CAM expression and their prognosis were not clear. Furthermore, this study did not refer to the surgical margin or lymph node metastasis, which was among the strongest prognostic factors. On the other hand, our study was limited to patients receiving radical surgery and elucidated that Ep-CAM was identified as an independent prognostic factor in multivariate analysis including the lymph node metastasis. The results in this study must reflect the significance of Ep-CAM expression in pancreatic cancer more accurately.
In this study, we divided enrolled patients into Ep-CAM high and low-expression group by four of Ep-CAM expression scoring and this cut-off line was based on the previous reports (Gastl et al., 2000; Varga et al., 2004; Fong et al., 2008; Noda et al., 2009) . However, as shown in Figure 2 , it might not be appropriate to set the cut-off line at four because there were many patients scoring between 4 and 6. So, we divided enrolled patients into three groups, 'high expression' with over 6 of scoring (n ¼ 20), 'middle expression' with 3-6 (n ¼ 55), and 'low expression' with under 3 (n ¼ 20), and we revaluated the significance of Ep-CAM expression in pancreatic cancer (Supplementary Figure 7 ). High-expression group showed better prognosis than the other two groups and the overall survival rate decreased gradually according to the level of Ep-CAM expression although the difference was marginally significant (P ¼ 0.090). This indicated that Ep-CAM expression was actually related to the prognosis of pancreatic cancer patients after radical resection.
Ep-CAM is reported to have many different roles in cancer; cell-adhesion, invasion and migration, proliferation and so on (Balzar et al., 1999a; Trzpis et al., 2007) . Considering our in vitro and in vivo result, the dominant role of Ep-CAM in pancreatic cancer may be related to the migration and invasion such as EMT. Ep-CAM expression is well related to E-cadherin (and possibly vimentin) expression, which is one of the most common EMT markers. Of course, the sample size of this study was very small and as a result, we could not find out the mechanism of Ep-CAM clearly at this time unfortunately, but we consider that Ep-CAM is at least partially connected to EMT in pancreatic cancer and more clinical samples and further research are needed to reveal it.
In conclusion, we elucidate Ep-CAM has an important role as a prognostic marker by suppressing cell activity in this study. Furthermore, it is meaningful that Ep-CAM may be more useful especially for patients without lymph node metastasis, because such patients are expected to get better prognosis by adding adequate additional therapy after resection. At present, there is no valuable biomarker to divide patients to good or bad prognostic group after resection, so we believe that this study will be a good help to the indication for pancreatic cancer patients to decide the adequate therapy.
Materials and methods

Cell culture
Three types of human pancreatic cancer cell lines were used in the present study. MiaPaCa-2 and PSN1 were obtained from the Japanese Collection of Research Bioresources (JCRB, Tokyo, Japan), and Panc1 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). All cell lines were cultured at 37 1C under 5% CO2 in DMEM (MiaPaCa-2 and Panc1) or RPMI1640 (PSN1) supplemented with 10% fetal bovine serum and 100 U/ml penicillin and 100 mg/ml streptomycin.
Gene transfection
Ep-CAM expression plasmid was purchased from OriGene Technologies Inc. (Rockville, MD, USA). Empty vector plasmid was also purchased from it and used to establish negative-control cells for the Ep-CAM-transfected cells. These plasmids were transfected into pancreatic cell lines using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the instructions provided by the manufacturer. After transfection of Ep-CAM expression plasmid, stable transfection were selected and maintained by adding 600 mg of G418 (Gibco-BRL, Grand Island, NY, USA). Successful transfection was confirmed by the real-time quantitative reverse transcription-PCR (qRT-PCR).
Real-time quantitative reverse transcription-PCR (qRT-PCR)
Total RNA was purified by RNeasy Mini Kit (QIAGEN, Tokyo, Japan), according to the manufacturer's instructions. Complementary DNA was generated from 1 mg RNA with avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI, USA) as previously described (Tsujie et al., 2003) . The qRT-PCR assays were carried out using the Light Cycler (Roche Diagnostics, Mannheim, Germany) as previously described (Ogawa et al., 2004) and the amount of target gene expression was calculated. The target gene expression was normalized relative to the expression of glyceraldehydes-3-phosphate dehydrogenase, which was used as an internal control. Gene expression was measured in triplicate. The designed PCR primers of each molecule were shown in Supplementary Table 3 .
Proliferation assay
In all, 5 Â 10 4 of each cell was seeded to a six-well plate with 2 ml of medium and left overnight to adhere. The medium was replaced daily with 2 ml of fresh medium. Each cell was harvested and the number of it was counted with an automatic cell counter (Nucleocounter, Chemometec, Allerod, Denmark) at 48, 72, 96 h after seeding. The difference of cell number was examined between Ep-CAM-transfected cells and the others.
Invasion and migration assay
The invasion and migration assays were performed using Transwell cell culture chambers (8 mm pore size polyethylene terephthalate membrane; BD Biosciences, Bedford, MA, USA) according to the manufacturer's instructions. The membrane for invasion assay was coated with Matrigel (BD Biosciences). Pancreatic cancer cells (3 Â 10 4 ), in serum-free media, were seeded in the upper chamber and 5% FBS was added as a chemoattractant in the lower chambers. After 24 incubations, the filters were stained with Diff-Quick kit (BD Biosciences), and the number of cells that had invaded through the filter was counted under a microscope. Five microscope fields were randomly selected for cell counting, and each assay was performed in triplicate.
Patient enrollment
This study was a multicenter study and patients were enrolled from Osaka Univ. and OMCC. This is a retrospective study, so to evaluate the significance of Ep-CAM expression accurately, patients who received preoperative therapy or whose surgery resulted in R1 (microscopic cancer residue) or R2 (macroscopic cancer residue) resection were excluded. According to these criteria, 82 patients in Osaka Univ. from 1992 to 2008 and 32 in OMCC from 1996 to 2001 were enrolled in this study. Among these 114 patients, neutral-buffered formalinfixed and paraffin-embedded tumor blocks and clinical followup information for study purposes was available in 68 in Osaka Univ. and 27 in OMCC. As a result, 95 patients were enrolled finally in this study. As the natural history for variant pancreatic neoplasms differs from usual pancreatic ductal adenocarcinoma, patients with intraductal papillary mucinous neoplasms, mucinous cystic adenocarcinomas and medullary adenocarcinomas were excluded.
Patient characteristics are shown in Table 3 . There were 51 men and 44 women with an average age of 66.0 þ 8.2 years. All patients had R0 (no residual cancer) resections by pancreaticoduodenectomy in 72 patients, distal pancreatectomy in 18 patients and other resections in 5 patients. The histopathological grading showed poorly, moderately and well differentiated adenocarcinoma in 11, 46 and 38 patients, respectively. The UICC-TNM classification was 4, 4 and 87 patients with pT1, pT2 and pT3; 40, 45 and 10 patients with pN0, pN1 and pM1lym; and 2, 3, 35, 45 and 10 patients with stage IA, IB, IIA, IIB and IV, respectively. None of the patients had received neoadjuvant therapy. Adjuvant therapy was performed in 21 patients. All 95 patients were followed until disease recurrence and/or death. The median follow-up period was 17.6 months (range, 4.3-145), the 5-year survival rate was 24.1%, and recurrence of disease was observed in 67 patients. There is no significant difference of patients' characteristics in between Osaka Univ. and OMCC.
Immunohistochemistry and evaluation of staining For immunohistochemical staining of Ep-CAM expression, we used the method as previously described (Noda et al., 2009) . For negative controls, sections were treated the same way except that they were incubated with Tris-buffered saline instead of the primary antibody and normal pancreatic duct epithelium present in each section and Ep-CAM-transfected pancreatic cancer cell lines (MiaPaCa-2 and PSN1) were used as positive controls. Ep-CAM expression was assessed by two investigators (HA and YT) independently without knowledge of the corresponding clinicopathological data. Ep-CAM expression was evaluated by calculating the total immunostaining score, representing the product of the proportion score and the intensity score as described in the previous report (Gastl et al., 2000) . In brief, the proportion score described the estimated fraction of positively stained tumor cells (0, none; 1, o10%; 2, 10-50%; 3, 50-80% and 4, 480%) and the intensity score represented the estimated staining intensity (0, no staining; 1, weak; 2, moderate; 3, strong). The total score was ranging from 0 to 12, and Ep-CAM positive cases represented those with a total score 44 according to previous reported creiteria (Gastl et al., 2000; Varga et al., 2004; Fong et al., 2008; Noda et al., 2009) . For the evaluation of heterogeneity in pancreatic cancer, the average score of triplicate tissues from each patient was used. The immunostaining of other molecules were performed in the same way as Ep-CAM. The list of primary antibody was shown in Supplementary Table 3 .
Statistical analysis and ethical issues
Data are expressed as mean ± s.d. Differences in continuous values were evaluated by the Student's t-test. The Fisher's exact probability test was used to compare discrete variables. Overall and disease-free survival rates were estimated by the KaplanMeier method and evaluated using the log-rank test. Cox's proportional hazard regression model with stepwise comparisons was used to analyze independent prognostic factors. A P-value o0.05 was used to indicate statistical significance.
The study protocol was approved by the Human Ethics Review Committee of both Osaka Univ. and OMCC, and a signed consent form was obtained from each subject. The significance of Ep-CAM expression in pancreatic cancer H Akita et al
